What does Schedule I mean for 7-OH?

At a glance: Schedule I and 7-OH (as of July 21, 2026)

Key Takeaways

• Schedule I is the federal government's most restrictive drug category. Once a substance is placed there, it cannot be prescribed, legally manufactured, or commercially sold.
• The order is not in effect yet. The DEA's notices of intent published July 6, 2026. The temporary scheduling order cannot issue before August 5, 2026.
• It targets concentrated products, not kratom leaf. The threshold — 0.05% 7-OH by dry weight — is designed to capture manufactured and synthetic products while explicitly not covering natural kratom leaf below that level.
• For most people using 7-OH, the practical change is availability, not prosecution. Products leave shelves. For someone dependent on daily 7-OH, that means involuntary withdrawal on a schedule set by federal law rather than a clinical plan.
• There is still a window. Between now and when the order takes effect, getting into treatment is a planned transition rather than a forced one.

What Schedule I actually means

The framework

The Controlled Substances Act of 1970 (21 U.S.C. § 812) organizes substances into five schedules based on three criteria: abuse potential, accepted medical use, and dependence risk. Schedule I sits at the top with the most restrictions.

To be placed in Schedule I, a substance must meet all three statutory criteria:

• High potential for abuse
• No currently accepted medical use in treatment in the United States
• Lack of accepted safety for use under medical supervision

When all three are met, the result is a category with no legal prescription pathway, no authorized commercial manufacture or distribution, and criminal penalties for violations under 21 U.S.C. § 841 (trafficking) and § 844 (simple possession).

What Schedule I prohibits

Once a substance is in Schedule I:

• No physician can prescribe it
• It cannot be legally manufactured, distributed, or sold
• It can only be handled for research under a federally approved DEA Schedule I research registration (which requires a separate, significant application process on top of FDA approval)
• Possession, distribution, and manufacturing are subject to federal criminal penalties

The company it keeps

Schedule I includes heroin, LSD, psilocybin, and, at the federal level, marijuana (despite many state-level authorizations). The comparison to heroin is what many people searching this topic are actually asking about.

Worth stating plainly: Schedule I reflects a legal determination about accepted medical use and abuse potential, not a scientific ranking of relative danger. Many substances in lower schedules are objectively more dangerous in clinical practice. The schedule is a legal category, not a toxicology gradient.

What would change for 7-OH specifically

For sellers and manufacturers

Once a temporary order takes effect, manufacturing, distributing, importing, and selling covered 7-OH products become violations of the Controlled Substances Act subject to the criminal, civil, and administrative provisions of 21 U.S.C. §§ 841 and 843. This is the mechanism that removes products from shelves. Retailers who continue selling covered products after the order takes effect face federal liability.

What is covered and what is not

The DEA's July 6, 2026 notices (Docket DEA-1570) specify two distinct scheduling actions:

Notice 1: 7-hydroxymitragynine above the threshold:

• More than 0.05% by dry weight in botanical or plant material
• More than 0.05% by concentration in any article, or more than 1.00 milligram of 7-OH per article, for synthetic or processed products

Notice 2: Three synthetic derivatives at any concentration:

• Mitragynine pseudoindoxyl (MP)
• MGM-15
• MGM-16

None of these three compounds occurs naturally in the kratom plant.

What is explicitly not covered: Botanical kratom leaf containing naturally occurring 7-OH below the 0.05% threshold. DEA and HHS officials stated clearly that this action does not target natural kratom leaf. The threshold was specifically designed to distinguish manufactured concentrate from botanical material. See Kratom vs. 7-OH for the pharmacological distinction.

For research

This is the counterintuitive consequence of Schedule I placement: it makes a substance harder to study. Researchers who want to investigate 7-OH — its pharmacology, its therapeutic potential, or its risks — would need both DEA Schedule I research registration and FDA approval, a dual-registration burden that substantially slows research timelines. Several scientists and policy observers have flagged this as a concern given how much about 7-OH's clinical profile remains unstudied.

What about possession?

This section states what federal law provides. It is not legal advice. Anyone with specific legal questions about their own situation should consult a criminal defense attorney or legal aid organization. This article does not predict how law enforcement will prioritize or pursue individual cases.

Federal law under 21 U.S.C. § 844 sets penalties for simple possession of a Schedule I controlled substance at up to one year of imprisonment and a mandatory minimum fine of $1,000 on a first offense, with increased penalties for subsequent offenses. Distribution and trafficking penalties under § 841 are substantially higher and vary by quantity.

This article does not tell you whether or how you would be prosecuted. Enforcement priorities, prosecutorial discretion, and local context vary significantly. The appropriate place for those questions is with an attorney.

State law is separate. Several states — including Florida, Tennessee, and Kansas — have already scheduled 7-OH or all kratom under state law, with their own enforcement frameworks. State-level restrictions apply independent of the federal scheduling action. See The 2026 7-OH Legal Landscape for state-by-state status.

Temporary vs. permanent scheduling

What "temporary" means procedurally

The DEA's authority to temporarily schedule a substance comes from 21 U.S.C. § 811(h), which allows the Attorney General to place a substance in Schedule I for up to two years (extendable by one additional year) to address an "imminent hazard to public safety," without completing the standard notice-and-comment rulemaking process.

A notable procedural feature: temporary scheduling orders under § 811(h) are explicitly not subject to judicial review, which has been a point of contention with advocacy groups who object to the process.

The temporary order runs while permanent scheduling is considered through the standard process, which involves a full scientific review, inter-agency assessment, and rulemaking.

The policy debate

Public health officials and kratom leaf advocates have supported this action, specifically because the threshold draws a clear line between concentrated manufactured products and natural leaf. HHS and FDA issued a joint statement supporting the DEA's action, citing 7-OH's opioid receptor activity, documented overdose deaths, and the absence of any accepted medical use.

Consumer choice advocates and 7-OH industry groups have objected to the use of emergency scheduling authority, arguing that it bypasses the full scientific review process at a moment when the research base is still developing. Some organizations have signaled intent to pursue legal challenges. The American Kratom Association, which represents botanical kratom consumers, has supported the action on the basis that it distinguishes the leaf from concentrated products.

This page reports those positions and does not take one.

What comes next

The HHS public comment window closed July 31, 2026. Permanent scheduling would follow the standard process — scientific review, inter-agency coordination, and rulemaking — which typically runs over one to three years. During that period, the temporary order remains in effect.

What this means if you use 7-OH

For most individual users of 7-OH, the consequential change when the order takes effect is not primarily legal exposure — it is that the products stop being available at gas stations, smoke shops, and online retailers. When that happens, someone who has been dosing daily faces involuntary withdrawal on a timeline set by federal law rather than a clinical plan.

7-OH withdrawal is opioid withdrawal. Onset typically begins 6 to 12 hours after the last dose for concentrated product users. The peak is hard. The relapse pull during the peak is strong. Facing that without preparation — because the product simply disappeared — is the worst version of stopping.

There is still a window between now and when the order takes effect. That window is the opportunity to get ahead of this: to start treatment before the supply ends rather than after, so that the transition is planned and supervised rather than forced and chaotic.

Buprenorphine (Suboxone) stabilizes the same opioid receptors that 7-OH was activating. It prevents the withdrawal that would otherwise be the only alternative to continued use. It is available through telehealth in most states. Starting now means the transition is yours to manage; waiting means it happens on the law's schedule.

For what withdrawal looks like: 7-OH Withdrawal Symptoms For what to do right now: 7-OH Is Being Banned: What to Do If You Use It to Cope For how treatment works: Does Suboxone Work for Kratom and 7-OH?

Frequently Asked Questions

Is 7-OH the same category as heroin under federal law?

Once the temporary scheduling order takes effect, yes — both would be Schedule I controlled substances under federal law. Schedule I is the legal category that produces this result; it reflects a determination about accepted medical use and abuse potential, not a scientific comparison of the two substances' relative dangers or effects. 7-OH and heroin have different chemistry, different pharmacokinetics, and different clinical profiles. The scheduling classification means the same legal framework applies to both.

Will I be arrested for having 7-OH?

This article does not answer that question. Federal law sets the penalty framework; enforcement decisions involve prosecutorial discretion, resource allocation, and context that vary significantly. Anyone with specific concerns about their legal situation should consult a criminal defense attorney or legal aid organization. This article is informational only.

What should I do with 7-OH products I have?

If you want to dispose of unused products, the DEA's Take Back Program provides authorized disposal sites. See the DEA's take-back guidance at https://www.dea.gov/takebackday for locations. This article does not advise on any other approach to product disposal.

Does the scheduling cover all kratom?

No. The DEA's action targets 7-OH above the 0.05% concentration threshold and three synthetic compounds. Botanical kratom leaf with naturally occurring 7-OH below that threshold is explicitly not covered by the federal scheduling action. State laws vary; some states have their own restrictions on kratom leaf. See the full legal landscape.

Is this permanent?

The temporary scheduling order would run for two years and can be extended by one additional year while permanent scheduling is considered. Permanent scheduling requires the standard rulemaking process and scientific review, which is a separate, slower proceeding. The temporary order is not the same as permanent Schedule I placement, though it produces similar immediate legal consequences while it is in effect.